Erratum

In the article “Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis” [Liver Cancer. 2025; https://doi.org/10.1159/000549955] by Chan et al., the copyright license has been changed to a CC-BY 4.0 license. The original online article has been updated to reflect this.

Publication Details

Journal
Liver Cancer
Published
2026-05-27
DOI
https://doi.org/10.1159/000552217
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Erratum

Liver Cancer
Hepatocellular Carcinoma Treatment and Prognosis
article

Erratum

article en

Abstract

In the article “Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis” [Liver Cancer. 2025; https://doi.org/10.1159/000549955] by Chan et al., the copyright license has been changed to a CC-BY 4.0 license. The original online article has been updated to reflect this.

Liver Cancer
No poverty
Openalex Percentile: Top 14%
Hepatocellular Carcinoma Treatment and Prognosis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.